Dose Dependent Effects on Cell Cycle Checkpoints and DNA Repair by Bendamustine

Neil Beeharry¹*, Jerome B. Rattner², Alfonso Bellacosa¹, Mitchell R. Smith¹, Timothy J. Yen¹*

1 Department of Cell Biology and Anatomy, University of Calgary, Calgary, Alberta, Canada
2 Department of Cell Biology and Anatomy, University of Washington, Seattle, Washington, United States of America

Abstract

Bendamustine (BDM) is an active chemotherapeutic agent approved in the U. S. for treating chronic lymphocytic leukemia and non-Hodgkin lymphoma. Its chemical structure suggests it may have alkylator and anti-metabolite activities; however, the precise mechanism of action is not well understood. Here we report the concentration-dependent effects of BDM on cell cycle, DNA damage, checkpoint response and cell death in HeLa cells. Low concentrations of BDM transiently arrested cells in G2, while a 4-fold higher concentration arrested cells in S phase. DNA damage at 50, but not 200 μM, was efficiently repaired after 48 h treatment, suggesting a difference in DNA repair efficiency at the two concentrations. Indeed, perturbing base-excision repair sensitized cells to lower concentrations of BDM. Timelapse studies of the checkpoint response to BDM showed that inhibiting Chk1 caused both the S- and G2-arrested cells to prematurely enter mitosis. However, whereas the cells arrested in G2 (low dose BDM) entered mitosis, segregated their chromosomes and divided normally, the S-phase arrested cells (high dose BDM) exhibited a highly aberrant mitosis, whereby EM images showed highly fragmented chromosomes. The vast majority of these cells died without ever exiting mitosis. Inhibiting the Chk1-dependent DNA damage checkpoint accelerated the time of killing by BDM. Our studies suggest that BDM may affect different biological processes depending on drug concentration. Sensitizing cells to killing by BDM can be achieved by inhibiting base-excision repair or disrupting the DNA damage checkpoint pathway.

Introduction

Bendamustine (BDM) represents one of the earliest rationally designed anticancer drugs that incorporated three functional groups; a benzimidazole ring, a methocarboxylamine group and a butanoic acid residue. These groups putatively endowed BDM with both alkylator and anti-metabolite activities. BDM has been found to be especially effective in hematologic-related cancers including multiple myeloma, chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) for which the FDA has approved its use, and multiple myeloma. Importantly, BDM is highly effective in NHL patients who have failed conventional alkylator therapies [1], thus supporting the idea that BDM has different mechanisms of action. Despite the many years of clinical use of BDM, and demonstration of ability to alkylate DNA, its precise mechanism of action in cells remains obscure. A central theme regarding BDM is whether or not it causes a different cellular insult as compared to standard alkylating agents (reviewed in [2]). A previous report suggested that the type of DNA damage induced by BDM was different to that caused by alkylating agents [3]. For example, the treatment of the non-Hodgkin lymphoma cell line SU-DHL-1 with BDM led to a greater increase in the expression of several p53-responsive genes and DNA damage/repair genes when compared to other alkylators. The differences in the expression pattern of genes involved in DNA-damage stress response, apoptosis, cell cycle, mitosis and DNA replication between BDM and standard alkylating agents suggested that BDM elicits a different cytotoxic response that was mediated by a mechanism of action unlike that of other alkylating agents [3]. Mechanistic studies using human CLL and mantle cell lymphoma (MCL) cell lines [4] and CLL cells from patients [5] point to activation of classical apoptosis through mitochondrial perturbation, Bax induction and activation, release of cytochrome C and subsequent caspase-3 activation after BDM treatment. Furthermore, by interrogating CLL and mantle cells from patients, Roue et al. found no correlation between p53 status and BDM cytotoxicity [4].

Less well studied is the connection between BDM and cell cycle progression. Myeloma cells treated with BDM at 10–30 μg/ml (equivalent to 25–76 μM) arrested in G2 [6], whilst SU-DHL-1 cells treated with BDM at 50 μM resulted in a modest S phase delay [3]. Whether the different cell cycle responses were due to idiosyncrasies of the cell lines or due to different concentrations of drug remains unclear. A major unaddressed question raised by these studies is whether cell cycle arrest induced by BDM is related to cell death. Here we set out to characterize the effect of BDM on cell cycle progression, DNA damage induction and repair, and cell viability.
Materials and Methods

Materials

Bendamustine, propidium iodide, chlorambucil, melphalan and Chk2 inhibitor II were all purchased from Sigma. The UCN-01 was generously provided by Kyowa Hakko Kirin Co., Ltd. and the National Cancer Institute, NIH.

Cell lines and culture conditions

All cell lines were originally obtained from the ATCC and banked at the Fox Chase Cancer Center (FCCC) Cell Culture facility. Mycoplasma testing was conducted at FCCC prior to studies. The cell lines HeLa, PANC1, BxPC3, MCF7, MDA-MB-435 were grown in DMEM supplemented with 10% FBS, 2 mM glutamine and 1% penicillin, streptomycin and kanamycin (PSK). OVCAR 5 and 10 cells were grown in RPMI supplemented with 10% FBS, 2 mM glutamine and 1% PSK. U2932 were grown in RPMI supplemented with 15% FBS, 2 mM glutamine and 1% PSK. Wildtype and TDG−/− MEFs, generated as previously described [7], were grown in DMEM supplemented with 15% FBS, 2 mM glutamine and 1% PSK. All cells were maintained at 37°C, 5% CO2.

Cell viability and apoptosis assays

HeLa cells were seeded into 96 well plates at a density of 1500 cells per well. Cells were treated with BDM (3.125–200 μM) for 24 h. After this time cells were additionally treated either with UCN-01 (100 nM), Chk2 inhibitor (100 nM) or Go6976 (200 nM) for an additional 24 h. MTS reagent (CellTiter 96® AQueous Proliferation Assay, Promega) was added to each well for 4 h before the absorbance values at 490 nm was read. Experiments were conducted in triplicate, 3 independent times. Data presented are the average absorbance values, relative to control ± SD. For apoptosis determination, cells seeded and treated as stated above were stained with Guava Nexin Reagent® (Millipore). Analysis was conducted using the Easycyte module and Cytosoft Software® (Millipore). Experiments were conducted 3 independent times, collecting 2000 events each time. Data shown is the average ± SD.

Clonogenic assay

HeLa cells were seeded into 6 well plates at a density of 1000 cells per well. Cells were treated with BDM (3.125–200 μM) for 24 h. After this time cells were additionally treated either with UCN-01 (100 nM), Chk2 inhibitor (100 nM) or Go6976 (200 nM) for an additional 24 h. MTS reagent (CellTiter 96® AQueous Proliferation Assay, Promega) was added to each well for 4 h before the absorbance values at 490 nm was read. Experiments were conducted in triplicate, 3 independent times. Data presented are the average absorbance values, relative to control ± SD. For apoptosis determination, cells seeded and treated as stated above were stained with Guava Nexin Reagent® (Millipore). Analysis was conducted using the Easycyte module and Cytosoft Software® (Millipore). Experiments were conducted 3 independent times, collecting 2000 events each time. Data shown is the average ± SD.

Metaphase spreads

Mitotic cells were collected from untreated and BDM at 50 μM or 200 μM+UCN-01 (100 nM) treatments. Cells for metaphase spreads were prepared as outlined by [8]. For visualizing, cells were dropped onto glass slides and stained with DAPI. Mitotic spreads were viewed and imaged using fluorescence microscopy. Images shown are representative of those observed.

Electron microscopy

HeLa cells were seeded into 6 cm dishes, synchronized with thymidine (2 mM) and treated with BDM 50 μM, 200 μM for 18 h. Cells treated with UCN-01 (100 μM) for an additional 9 h to obtain mitotic cells were fixed with glutaraldehyde solution (3%, pH 7.4). Samples were prepared for electron microscopy analysis as previously described [9].

Immunofluorescence

Cells were grown on coverslips, treated with the indicated drugs, fixed and stained as previously described [10]. To detect DNA damage induction and repair, antibodies against 53BP1 (Bethyl) and γ-H2AX (Upstate) were used with Alexa Fluor-conjugated secondary antibodies (Invitrogen). All cells were counter-stained with DAPI (Molecular Probes). Images were captured using a 40× or 100× objective mounted on an inverted microscope (Eclipse TE2000S; Nikon) with a CCD camera (Photometrics Cascade 512F; Roper Scientific) powered by NIS Elements AR (version 3.10) software (Nikon). For quantitative analysis, individual nuclei were identified using DAPI staining and used to define regions of interest (ROI), which were then transposed onto other channels. The sum intensity per nuclei from a minimum of 50 nuclei was averaged ± SEM.

EdU incorporation

HeLa cells were treated with nocodazole for 14 h after which time mitotic cells were collected by mechanical shake-off. Cells were washed twice with medium and re-plated. BDM and EdU (10 μM) (Click-iTTM EdU imaging kit, Invitrogen) were added 2 h later, when the cells were fully adherent and still in G1, and incubated for an additional 12 h. Cells were fixed and stained according to the manufacturer’s protocol. Quantification of EdU incorporation was performed as described for antibody detection.

Time-lapse video microscopy

HeLa cells stably expressing green fluorescent protein (GFP); histone H2B were seeded into 6 well plates and synchronized in S phase using thymidine (2 mM). Thymidine was washed out and 11 h later, cells were treated with the indicated drugs for an additional 18 h. Where appropriate, UCN-01 (100 nM) was added to wells before being supplemented with HEPES (25 mM), layered with mineral oil (Sigma) and placed into a housing chamber which maintained the temperature at 37°C. Using a Nikon TE2000 microscope (Nikon) controlled by MetaMorph software (Molecular Devices), bright field and fluorescent images were captured every 5 minutes for up to 48 h. Individual movies were analyzed manually and a minimum of 100 cells per treatment scored for the indicated measurements. For montages, selected frames representing different cell morphologies are presented.

DNA content analysis via flow cytometry

Following indicated drug treatments, cells were fixed with 70% ethanol. For analysis, cells were stained with propidium iodide, RNase A and sodium citrate. Cells were incubated at 37°C for 30 minutes before being analyzed using a Becton Dickinson single laser three-fluorescence FACScan flow analyzer and Cell Quest software (Becton Dickinson). DNA content was acquired from 10,000 events and FlowJo software was used to process the data.

Statistical analysis

For statistical analyses, Student’s two-tailed t test was conducted.
Results

BDM displays concentration-dependent effects on cell cycle response

HeLa cells synchronized in G1 by release from a mitotic shake-off were treated with increasing concentrations of BDM and their cell cycle profiles were assessed 24 h later. Figure 1 shows that HeLa cells treated with increasing doses of BDM (25–100 μM) accumulated at a 4 N DNA content indicating a G2/M delay. In contrast, cells treated with 200 μM BDM were arrested in S phase. We next confirmed the dose-dependent effects of BDM on the cell cycle in a wide panel of cancer cell lines. Cell lines derived from pancreatic (PANC1 and BXPC3 cells), breast (MCF7 and MDAMB-435), and ovarian (OVCAR 5 and 10) cancers responded similarly to HeLa cells (Fig. 1 and Figure S1) in that 50 μM BDM caused a G2 arrest while 200 μM BDM resulted in an S phase arrest. The concentrations of BDM used here are consistent with those previously used against a number of epithelial derived cell lines [11,12], but are generally higher than concentrations used for leukemic cell lines [12]. To test if this was a feature of adherent cell lines, we treated the U2932 cells (B cell lymphoma) with BDM. As seen with the adherent cell lines, U2932 cells also exhibited a dose dependent cell cycle response, but at a lower concentration: 10 μM induced a G2 arrest, 50 μM induced an S phase arrest. The combined data demonstrate that BDM induces a dose-dependent effect on cell cycle progression in multiple cell lines.

We measured DNA synthesis to further assess the effects of BDM on cell cycle progression. HeLa cells synchronized by mitotic shake-off were treated in G1 with either 50 or 200 μM BDM in the presence of EdU (10 μM) for 12 h. Cells treated with 50 μM BDM incorporated essentially the same amount of EdU (98.0±4.1%) as untreated cells (100±4.8%), while cells treated with 200 μM BDM incorporated only 64.7±2.6% as compared to untreated cells (p = 1.1×10^-16). This suggests that 200 μM BDM reduces the efficiency of replication, consistent with the delay in S phase progression. Although replication was not grossly affected by 50 μM BDM, the G2 delay may reflect accumulation of replication errors that did escape the S phase checkpoint.

Bendamustine induces both repairable and irreparable DNA damage

The cell cycle arrest observed in Figure 1 was likely a result of BDM-induced DNA damage, activating the DNA damage checkpoint pathway. We therefore examined phospho-H2AX (Ser 139), 53BP1 and replication protein A (RPA), three different DNA damage response proteins, as a direct measure of BDM-induced DNA damage. We found that BDM induced H2AX foci, reflecting accumulation at sites of DNA damage (Figure 2A). We observed a concentration-dependent increase in γ-H2AX foci after 24 h treatment. However, after 48 h of treatment with 50 μM BDM γ-H2AX foci was reduced to levels seen in vehicle-treated cells (Figure 2A). The reduction in H2AX was likely a result of efficient DNA repair. However, after 48 h treatment with 200 μM BDM the level of H2AX foci was not reduced. We next confirmed these results by staining for 53BP1 and RPA. After 24 h treatment we observed a dose-dependent increase in foci formation, as seen with H2AX foci. Furthermore, after 48 h with 50 μM BDM levels of 53BP1 and RPA were reduced to control levels. In contrast, foci formation persisted after 48 h continuous treatment with 200 μM BDM.

We next compared the cell cycle profiles of cells treated with 50 μM or 200 μM for 24 h, 48 h continuously or for 24 h with BDM, followed by 24 h in the absence of drug. Figure S2 shows the expected cell cycle arrest after treatment with 50 μM BDM for 24 h, but after another 24 h in the presence or absence of BDM, cells displayed a normal cell cycle profile. This is consistent with the efficient repair (lack of foci) of DNA damage at 50 μM BDM.

In contrast, the cell cycle arrest induced by 200 μM BDM was maintained following 40 h continuous treatment, and even 24 h after BDM was washed out, this did not reverse the arrest. This finding is consistent with the persistent DNA damage foci at 200 μM BDM.

Since Chk1 is a key regulator of cell cycle response following cellular exposure to replication stress, we assessed Chk1 phosphorylation (Ser-345) as a biochemical readout for cellular response to BDM. We observed that Chk1 was dose-dependently phosphorylated by BDM after 24 h treatment (Fig. 2B). Importantly, after 48 h no signal was observed in cells treated with 50 μM BDM as would be predicted from the IF and cell cycle data. However, detectable pChk1 was still present in cells treated with 200 μM BDM, confirming these cells were still checkpoint arrested. Taken together, these data suggest that DNA damage induced by 50 μM BDM is efficiently repaired, but at 200 μM BDM the effects on cell cycle and DNA damage were irreversible.

Involvement of base excision repair in bendamustine-induced DNA damage

A previous study showed that BDM-induced cell death was enhanced by an inhibitor of base excision repair (BER) [3]. We therefore sought to test the involvement of BER in whether BDM-induced damage. We targeted the essential BER protein apurinic/apyrimidinic endonuclease (APE1) by using the pharmacological inhibitor methoxyamine (MX) [13]. We treated HeLa cells with BDM 50 μM in the presence and absence of methoxyamine and assessed DNA damage. Untreated or cells treated with BDM 50 μM for 48 h had little γ-H2AX foci, as expected (from figure 2A). However, addition of MX to BDM-treated cells resulted in the retention of significantly higher levels of γ-H2AX foci than BDM alone or control cells (Fig. 3A). In contrast, using NU7441, a DNA-PK inhibitor that does not block BER, did not affect repair of BDM-induced damage.

Thymine DNA Glycosylase (TDG) is a prominent BER enzyme whose levels are regulated during the cell cycle [14]. For this reason, we tested its involvement in BDM-induced damage. We studied an isogenic pair of mouse embryonic fibroblasts (MEFs) that were either wild type (Tdg+/+) or with a genetic ablation of the Tdg gene (Tdg−/−) [7]. Not only did we observe that Tdg−/− MEFs were more sensitive to 10 μM BDM than wild type MEFs, showing increased γ-H2AX staining after 24 h of treatment, but they also had a reduced ability to repair the DNA damage after 48 h continuous treatment, as compared to wild type MEFs (Fig. 3B).

Chk1 inhibition accelerates bendamustine-induced cell death

Since recent pharmacokinetic studies demonstrated that BDM is rapidly metabolized in patients [15,16], we modified the clonogenic assay to assess how transient exposure to BDM affects long term survival. HeLa cells were treated for 24 h with BDM at 50 μM and 200 μM after which time drugs were washed out, replaced with fresh medium and allowed to recover. As shown in Figure 4A, colony formation between control cells versus cells treated with 50 μM BDM was marginally reduced (control 100±8.1% versus 87.8±11.2%; p<0.05). However, cells treated with BDM 200 μM showed a dramatic reduction in the number of colonies formed (control 100±8.1% versus 3.5±1.3%; p<0.0001).
Thus, concentrations of BDM (200 μM) that induced irreparable DNA damage and a sustained cell cycle arrest leads to efficient cell death. However, given the timescale reflected in the clonogenic assay after treatment with BDM 200 μM (~10 days), it is possible cells may acquire resistance to the drug and escape death. Since BDM 200 μM induced a sustained cell cycle arrest, we hypothesized that abrogating the checkpoint would accelerate killing by BDM. Figure 4B shows that BDM at any concentration (3.125–200 μM) is not particularly effective at killing HeLa cells after 48 h of continuous treatment. We next successively treated cells with BDM (3.125–200 μM) for 24 hours and then added UCN-01 (100 nM) for another 24 h, before assaying for cell viability. UCN-01 did not sensitize cells pre-treated with BDM up to 100 μM to killing. In contrast, viability was significantly
reduced in cells pre-treated with 200 \text{ M} BDM followed by UCN-01. Similar sensitization was observed with Go6976, another compound that inhibits Chk1 (data not shown). A pharmacological inhibitor of Chk2 did not sensitize to killing by any concentration of BDM in the same range.

Having demonstrated HeLa cell death was increased after BDM 200 \text{ M} + UCN-01, but not BDM 50 \text{ M} + UCN-01, we next examined the nature of killing. Cells were stained to discriminate between necrotic or apoptotic cell death. Notably, only cells treated with BDM 200 \text{ M} + UCN-01 or Go6976 exhibited an increase in the percentage of apoptotic cells (p < 0.01 vs. control) (Figure 4C and data not shown). It should be noted that UCN-01 alone had no discernable effects on cell viability in any of the assays performed. Taken together, these findings demonstrate that forcing cells to overcome the checkpoint induced by 200 \text{ M} BDM, but not 50 \text{ M}, BDM causes cells to die more effectively compared to cells treated with BDM alone.

Overcoming bendamustine-induced checkpoint arrest via Chk1 inhibition forces cells into premature mitosis

To gain insight as to how inhibition of Chk1 accelerated cell killing by 200 \text{ M} BDM, the fates of individual cells were tracked by time-lapse microscopy. HeLa cells stably expressing GFP:Histone H2B were treated with vehicle, 50 \text{ M} or 200 \text{ M} of BDM for 24 h before UCN-01 (100 nM) was added. The time-lapse data showed that vehicle treated cells entered and progressed normally through mitosis (average time of mitosis = 52.5 \pm 16.7 minutes) (Figure 5A, upper panel and Fig. S2). 50 \text{ M} BDM caused a reduction in the percentage of cells entering mitosis over a 24 h period (Fig S2), consistent with the G2 arrest observed by FACS analysis. Addition of UCN-01 abrogated the arrest and cells began to enter mitosis 4 hours later (Figure 5A, middle panel). While chromosome congression and alignment appeared normal, cells were nevertheless delayed at metaphase for an average of 89 \pm 64.7 minutes, as compared to controls that exited 37.5 \pm 16.7 minutes after metaphase alignment. Upon exiting mitosis, a fraction of cells exhibited chromosomal aberrations.
such as lagging chromosomes (Fig S3). Similarly, cells treated with 200 μM BDM had a reduced mitotic index, consistent with the cell cycle data. Inhibition of Chk1 induced mitotic entry but, unlike at 50 μM BDM, the mitotic figures of these cells were highly abnormal (Figure 5A, bottom panel). For example the chromosomes failed to align at the spindle equator, and cells rarely exited mitosis but instead died without exiting. The few cells that did exit formed multinucleated cells. Thus, cells forced into mitosis after 50 μM BDM + Chk1 inhibition progress through mitosis relatively normally. In contrast, cells forced into mitosis after 200 μM BDM + Chk1 inhibition generate extremely abnormal mitotic figures, with the majority failing to exit and instead dying in mitosis (Fig S3).

We next examined the chromosome morphology of cells that were forced to enter mitosis after treatment with 50 μM or 200 μM BDM+UCN-01 in greater detail. Metaphase spreads obtained from control and BDM 50 μM+UCN-01 treated cells showed no obvious gross structural defects (Figure 5B). In contrast, the metaphase spreads of BDM 200 μM+UCN-01 samples were extremely abnormal. Instead of forming discrete chromosomes, they appeared ‘pulverized’, a phenotype indicative of extensive chromosome fragmentation [17]. We therefore used electron microscopy to examine the ultra-structure of chromosomes after different drug treatments.

Figure 3. Involvement of base excision repair in bendamustine-induced DNA damage. A. Immunofluorescence analyses were performed to detect remaining γ-H2AX foci after 48 h continuous treatment with 50 μM BDM in the presence or absence of either methoxyamine (MX) (6 mM) or the DNA PK inhibitor NU7441 (10 μM). Representative images are shown (left) along with quantitative analysis (right). Average values ± SD are shown. *P<0.005 vs. BDM alone. B. DNA damage induction and repair was conducted in assessed MEFs (Tdg+/− and Tdg−/−) after treatment with BDM at 50 or 200 μM BDM for 24 h or 48 h. Representative images are shown, with nuclei outlined (circles) based on DAPI staining. Average γ-H2AX signal per nucleus ± SD is quantified (right). 24 h: *p = 0.009, **p = 2.0×10⁻⁵, ***p = 4.7×10⁻¹⁸ vs. untreated WT; †p = 0.00015, ‡p = 2.8×10⁻¹⁵, ‡‡p = 5.2×10⁻¹⁰ vs. untreated TDG −/−. 48 h: ***p = 4.1×10⁻¹⁰ vs. untreated WT; †p = 0.009, **p = 1.4×10⁻¹⁶, ***p = 1.9×10⁻¹⁶ vs. untreated TDG −/−.

doi:10.1371/journal.pone.0040342.g003
Figure 4. Chk1 inhibition accelerates bendamustine-induced cell death. A. Clonogenic assays were performed to assess cell survival following BDM and Chk1 inhibition. HeLa cells were treated with BDM (50 or 200 μM) for 24 h. Cells were grown for 10 days before being fixed and stained. The data presented are the mean absorbance value (O.D. 595 nm) relative to untreated cells, which is set to 100%. Each bar graph represents the average of 3 individual experiments performed in triplicate ± SD. †P<0.05 or *P<0.0001 vs. untreated cells.

B. Cell viability assessed by MTS assay was performed. HeLa cells were treated with BDM (3.125–200 μM) for 24 h. After this time, appropriate wells were co-treated with UCN-01 (100 nM) or Chk2 inhibitor (100 nM) for an additional 24 h. Data presented is the mean of 3 individual experiments performed in triplicate. Cell viability is expressed as a percentage of untreated cells ± SD. *P<0.0001 vs. 200 μM BDM alone.

C. The percentage of apoptotic cells following indicated drug treatments was determined using Guava Nexin Reagent™. Data presented is the average of 3 individual experiments ± SD. †P<0.01 vs. untreated viable cells; †P<0.01 vs. untreated apoptotic cells.
Figure 5. Overcoming bendamustine-induced checkpoint arrest via Chk1 inhibition forces cells into premature mitosis. HeLa cells stably expressing GFP:histone H2B were used for live cell video-microscopy. A. Representative montage of cells progressing through mitosis after mock treatment (upper panel), BDM at 50 μM (middle) or 200 μM (lower) followed by UCN-01 addition. B. Mitotic cells were fixed for metaphase spreads and dispersed onto glass slides, allowed to dry and then stained with DAPI. Metaphases were visualized using fluorescence microscopy. Images shown are representative of metaphases observed under each experimental condition. C. Representative electron micrographs of mitotic cells generated from untreated, 50 μM or 200 μM BDM+UCN-01 treatments.

(Fig. 5C). In control cells, as well as in mitotic cells obtained after treatment with BDM 50 μM+UCN-01, intact chromosomes were clearly visualized. However, in mitotic cells generated by the treatment with BDM 200 μM+UCN-01 chromosomes were highly fragmented.

Discussion

The studies described here show that BDM can induce an S or G2 cell cycle arrest depending on its concentration. This effect was not idiosyncratic of HeLa cells, as it was observed in cell lines derived from pancreatic, breast and ovarian cancers, at similar concentrations of BDM. We found that only a ∼four-fold difference (50 and 200 μM for adherent cells, 10 and 50 μM for lymphoblast) in concentration can change the cell cycle response from a G2 to an S phase arrest. The maximum concentration of BDM used in this study, 200 μM, to elicit cell cycle perturbations in ‘solid’ cancer cell lines are consistent with the IC50 values obtained in previous studies [12]. While 200 μM is ∼8–13 times higher than clinically achieved [16,19], the lymphoma cell line U2932 did show the same dose-dependent cell cycle arrest at more clinically relevant concentrations of BDM; cells treated with 10 μM BDM resulted in a G2 arrest, while 25 μM BDM resulted in an S phase arrest. These findings suggest that the hematologic malignancies may be more sensitive than cell lines derived from
The induction of S phase arrest. The studies presented here do not resolve the whether BDM acts as an alkylator, as an anti-metabolite or a combination of the two. However, we show that BDM at 50 μM and 200 μM has distinct effects on cell cycle and induction of DNA damage. Notably, the repair capacity after treatment with 50 μM and 200 μM is distinct: after 48 h continuous exposure, cells treated with 50 μM BDM exhibited no discernable markers of DNA damage, indicating that the damage was efficiently repaired. Moreover, cells were no longer arrested in G2 but were cycling normally, further suggesting repair of DNA damage. In contrast, cells treated with 200 μM BDM for 48 h failed to repair the damage, as shown by persistent γH2AX foci and sustained cell cycle arrest. Thus, these data support the notion that DNA damage induced by 200 μM BDM is repaired much less efficiently than at 50 μM. Furthermore, these findings are consistent with observations that not only does BDM induce more DNA double strand breaks as compared to the alkylating agents cyclophosphamide and BCNU, but also the BDM-induced damage is not repaired as efficiently as these two drugs [11]. Our studies are unable to distinguish between several distinct, but not necessarily mutually exclusive models that may account for the generation of irreparable DNA damage. The most simplistic explanation is that the amount of damage induced at 200 μM may quantitatively overwhelm the repair capacity of the cell to an extent that it slows down DNA replication. Another possibility is that 200 μM BDM may induce damage that differs qualitatively from that achieved with 50 μM BDM. A third possibility suggests that 200 μM BDM may inhibit proteins that are essential for repair. It is possible that the purine-like ring structure within BDM induces key proteins that require nucleotides for their activity (DNA polymerases, kinases, helicases). For example, caffeine contains a purine ring and can inhibit the activity of ATM and ATR, key kinases involved in double strand break repair [20]. Finally, BDM may be metabolized differently at the two doses such that only the higher concentration of BDM (200 μM) is present long enough to cause irreversible damage to DNA. Further studies are needed to test these hypotheses.

Our study highlights the potential use of combining BDM with inhibitors of DNA repair for therapeutic relevance. Using a combination of cell lines genetically ablated for TDG, as well as pharmacological inhibition of BER, indicates that at least a fraction of BDM-induced damage is repaired by BER. However, we note that repair is attenuated and not completely ablated, suggesting the involvement of other pathways. It is possible that mismatch repair that is known to mediate cytotoxicity of alkylating agents [21] may be involved in the repair of BDM-induced damage. Nonetheless, previous findings demonstrating that BDM-induced cytotoxicity was enhanced by co-treating cells with methoxyamine [3] suggest that combinatorial treatment of BDM with inhibitors of DNA repair may translate to therapeutic efficacy.

The difference in DNA damage repair efficiency between the two concentrations of BDM may help explain our findings on short-term and long-term cell viability. Our findings imply that short-term exposure (24–48 h) to BDM at 50 μM induces transient DNA damage which the cell eventually repairs, leading to no discernable long-term effects as determined by clonogenic survival assays. At 200 μM BDM, damage is not repaired and a 95% reduction in clonogenic survival is observed.

We are currently unsure as to how cells die after treatment with 200 μM BDM but the short-term assays provide clues. Using short-term assays, 48 h continuous exposure to BDM up to 200 μM did not reduce cell viability as compared to control treatment. Thus, the time and concentration of BDM is sufficient to activate cell cycle arrest but not to trigger apoptosis. Cell cycle arrest with 200 μM BDM presented us the opportunity to test the effect of Chk1 inhibition. Indeed, combining Chk1 inhibitors with conventional chemotherapy has proved beneficial in pre-clinical models of pancreatic cancer [22]. We showed that the inhibition of Chk1, but not Chk2, enhanced killing of BDM-treated HeLa in a short-term assay. The ineffectiveness of Chk2 inhibitors was previously reported in a multiple myeloma cell line, despite the fact that BDM treatment activated Chk2 [6]. It is pertinent to note that sensitization by Chk1 inhibitors only occurred with 200 μM of BDM, the dose that elicited an S phase arrest. Using a combination of live-cell video-microscopy, metaphase spreads and EM, we show that the majority of the cells exhibiting extremely abnormal mitoses end up dying in mitosis. By killing cells in mitosis, this combinatorial treatment could reduce the number of cells that divide, survive, and potentially become refractory to treatment. Thus, treatment of cancers with BDM in combination with Chk1 inhibitors may provide a novel therapeutic strategy that warrants further investigation; however, this would still critically depend on the concentration of BDM that elicits an S phase arrest, rather than a G2 arrest in order to kill cancer cells.

Supporting Information

Figure S1 BDM induces cell cycle arrest in multiple cell lines. Indicated cell lines were treated with increasing concentration of BDM for 24 h. Cell cycle profiles were determined using FACs analysis. (TIF)

Figure S2 Bendamustine concentration-dependent reversible and irreversible cell cycle arrest. Hela cells treated with 50 or 200 μM BDM for 24, 48 or 24 h in the presence of drug followed by 24 h in the absence of drug (24 h→24 h wash out (w/o) were analyzed for cell cycle distribution using FACs analysis. (TIF)

Figure S3 Forced entry mitosis results in aberrant mitosis. A. Quantification from the movie analysis was performed to measure the of the average time taken (minutes) to enter and exit mitosis ± SD (left panel) and the percentage of mitotic cells that displayed defects including lagging chromosomes or improper chromosome condensation (right panel). B. Quantification of the percentage of cells that enter mitosis of die in interphase after drug treatments (left panel), and measuring the fate of cells that enter mitosis (right panel). (TIF)

Acknowledgments

We thank the Imaging Facility and the High Throughput Screening and Translational Research Facility at Fox Chase Cancer Center for providing assistance with equipment and technical advice.

Author Contributions

Conceived and designed the experiments: NB MRS TJY. Performed the experiments: NB JBR TJY. Analyzed the data: NB TJY. Contributed reagents/materials/analysis tools: NB AB JBR MRS TJY. Wrote the paper: NB TJY.

Bendamustine Activates Cell Cycle Checkpoints
References

1. Heider A, Niederle N (2001) Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin’s lymphomas. Anticancer Drugs 12: 725–9.
2. Hartley JA, Leoni LM (2011) Mechanism of Action: The Unique Pattern of Bendamustine-Induced Cytotoxicity. Seminars in Hematology 48: S12–S23.
3. Leoni LM, Bailey B, Reifert J, Bendlall HH, Zeller RW, et al. (2008) Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 14: 309–17.
4. Roue G, Lopez-Guerra M, Milpied P, Perez-Galan P, Villamor N, et al. (2008) Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling. Clin Cancer Res 14: 6907–15.
5. Schwanen C, Hecker T, Hubinger G, Wolfle M, Ringen W, et al. (2002) In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. Leukemia 16: 2096–105.
6. Gaul L, Mandl-Weber S, Baumann P, Emmerich B, Schmidmaier R (2008) Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways. J Cancer Res Clin Oncol 134: 245–53.
7. Cortellino S, Xu JF, Sannai M, Moore R, Caretti E, et al. (2011) Thymine DNA Glycosylase Is Essential for Active DNA Demethylation by Linked Deamination-Base Excision Repair. Cell 146: 67–79.
8. Henegariu O, Heerema NA, Lowe Wright L, Bray-Ward P, Ward DC, et al. (2001) Improvements in cytogenetic slide preparation: controlled chromosome spreading, chemical aging and gradual denaturing. Cytometry 43: 101–9.
9. Rattner JB, Wang T (1992) Kinetochore formation and behaviour following premature chromosome condensation. J Cell Sci 103 ( Pt 4): 1039–45.
10. Feng J, Huang H, Yen TJ (2006) CENP-F is a novel microtubule-binding protein that is essential for kinetochore attachments and affects the duration of the mitotic checkpoint delay. Chromosoma 115: 320–9.
11. Strumberg D, Harstrick A, Doll K, Hoffmann B, Serber S (1996) Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 7: 415–21.
12. Konstantinov SM, Kostovski A, Topashka-Ancheva M, Genova M, Berger MR (2002) Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines. J Cancer Res Clin Oncol 128: 271–8.
13. Leoni LM, Bendlall HH, Zeller RW, et al. (2008) Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 14: 309–17.
14. Cortazar D, Kunz C, Saito Y, Steinacher R, Schar P (2007) The enigmatic thymine DNA glycosylase. DNA Repair (Amst) 6: 489–504.
15. Owen JS, Molhem M, Passarell JA, D’Andrea D, Darwish M, et al. (2010) Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin’s lymphoma. Cancer Chemother Pharmacol 66: 1039–49.